The present application describes methods of treating obesity using DGAT-1 inhibitors according to Formula I: including all prodrugs, solvates, pharmaceutically acceptable salts and stereoisomers, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and Z are described herein.